# Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)

> **NCT04502082** · PHASE1 · TERMINATED · sponsor: **Eureka Therapeutics Inc.** · enrollment: 8 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Liver Cancer
- Liver Neoplasm
- Metastatic Liver Cancer

## Interventions

- **BIOLOGICAL:** ET140203 autologous T cell product

## Key facts

- **NCT ID:** NCT04502082
- **Lead sponsor:** Eureka Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-14
- **Primary completion:** 2024-08-30
- **Final completion:** 2024-08-30
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The trial was intended to be a Phase 1/2 trial, but the sponsor terminated the trial prior to moving to Phase 2 to direct efforts to the pediatric study (ARYA-2) for this product.
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04502082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04502082, "Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04502082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*